{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:37:52Z","timestamp":1783960672207,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bioorg.2025.108154","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T11:55:37Z","timestamp":1736510137000},"page":"108154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Synthesis of new functionalized bioactive S-substituted indolyl-triazoles as cytotoxic and apoptotic agents through multi-targeted kinase inhibition"],"prefix":"10.1016","volume":"156","author":[{"given":"Ahmed T.A.","family":"Boraei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Nafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assem","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshu","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.M.","family":"Sarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2025.108154_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108154_b0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.108154_b0015","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1016\/j.ejmech.2010.05.072","article-title":"Synthesis and biological evaluation of novel 2, 4\u2032-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors","volume":"45","author":"Abou-Seri","year":"2010","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108154_b0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1042\/bj3510289","article-title":"Meaningful relationships: the regulation of the Ras\/Raf\/MEK\/ERK pathway by protein interactions","volume":"351","author":"Kolch","year":"2000","journal-title":"Biochem. J."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108154_b0025","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS\u2013ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108154_b0030","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/cdd.2008.148","article-title":"Tumour cell survival signalling by the ERK1\/2 pathway","volume":"16","author":"Balmanno","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioorg.2025.108154_b0035","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1016\/j.bmcl.2008.09.058","article-title":"Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening","volume":"18","author":"Park","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108154_b0040","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2174\/1568026023393318","article-title":"Targeting serine\/threonine protein kinase B\/Akt and cell-cycle checkpoint kinases for treating cancer","volume":"2","author":"Li","year":"2002","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108154_b0045","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.bmcl.2008.01.054","article-title":"Development of pyridopyrimidines as potent Akt1\/2 inhibitors","volume":"18","author":"Wu","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108154_b0050","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1016\/j.bmcl.2008.05.085","article-title":"Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors","volume":"18","author":"Siu","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108154_b0055","first-page":"133","article-title":"Antitumoral effect of 1, 2, 4\u2013Triazole derivatives on prostate carcinoma (DU145), Human Liver carcinoma (HEPG2), and Human Breast Cancer (MCF7) cell Lines","volume":"7","author":"Hassan","year":"2013","journal-title":"Australian J. Basic Appl. Sci."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108154_b0060","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.bmcl.2013.02.029","article-title":"Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1, 2, 4-triazol-4-amines as Bcl-2 inhibitory anticancer agents","volume":"23","author":"Hamdy","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108154_b0065","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejmech.2014.03.018","article-title":"Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids","volume":"77","author":"Nepali","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108154_b0070","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/jm061142s","article-title":"Highly potent triazole-based tubulin polymerization inhibitors","volume":"50","author":"Zhang","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108154_b0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejmech.2016.09.046","article-title":"Design, selective alkylation and X-ray crystal structure determination of dihydro-indolyl-1, 2, 4-triazole-3-thione and its 3-benzylsulfanyl analogue as potent anticancer agents","volume":"125","author":"Boraei","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108154_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111621","article-title":"Discovery of novel functionalized 1, 2, 4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation","volume":"182","author":"Boraei","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108154_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104330","article-title":"Farghaly, Discovery of novel indolyl-1, 2, 4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity","volume":"105","author":"Al-Hussain","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108154_b0090","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.3390\/biomedicines11113078","article-title":"Synthesis, Cytotoxic, and Computational Screening of Some Novel Indole\u20131, 2, 4-Triazole-Based S-Alkylated N-Aryl Acetamides","volume":"11","author":"Zahoor","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108154_b0095","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1940-6207.CAPR-11-0158","article-title":"(3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo","volume":"4","author":"Kim","year":"2011","journal-title":"Cancer Prev. Res."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108154_b0100","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41419-020-03108-2","article-title":"Indole hydrazide compound ZJQ-24 inhibits angiogenesis and induces apoptosis cell death through abrogation of AKT\/mTOR pathway in hepatocellular carcinoma","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2025.108154_b0105","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.3390\/molecules27206960","article-title":"Design, Synthesis, Anti-cancer Activity and Molecular Docking of New 1,2,3-Triazole-Based Glycosides Bearing 1,3,4-Thiadiazolyl Indolyl and Arylacetamide Scaffolds","volume":"27","author":"Elganzory","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108154_b0110","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.3390\/ijms23126548","article-title":"Synthesis and Anti-Cancer Activity of New Pyrazolinyl-Indole Derivatives: Pharmacophoric Interactions and Docking Studies for Identifying New EGFR Inhibitors","volume":"23","author":"Khalilullah","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108154_b0115","doi-asserted-by":"crossref","unstructured":"E. Mahmoud, D. Abdelhamid, B.G. Youssif, H.A. Gomaa, HA.M. Hayallah, M.Abdel\u2010Aziz, Design, synthesis, and anti-proliferative activity of new indole\/1,2,4-triazole\/chalcone hybrids as EGFR and\/or c-MET inhibitors, Arch. Pharm. 357(2024) e2300562.","DOI":"10.1002\/ardp.202300562"},{"key":"10.1016\/j.bioorg.2025.108154_b0120","doi-asserted-by":"crossref","first-page":"45665","DOI":"10.1021\/acsomega.2c06531","article-title":"Synthesis of New Bioactive Indolyl-1,2,4-Triazole Hybrids As Dual Inhibitors for EGFR\/PARP-1 Targeting Breast and Liver Cancer Cells","volume":"7","author":"Youssef","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2025.108154_b0125","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbrc.2018.09.120","article-title":"Oral administration of indole substituted dipyrido[2,3-d]pyrimidine derivative exhibits anti-tumor activity via inhibiting AKT and ERK1\/2 on hepatocellular carcinoma","volume":"505","author":"Gao","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.108154_b0130","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.bcp.2007.11.013","article-title":"JM91, a newly synthesized indoledione derivative, inhibits rat aortic vascular smooth muscle cells proliferation and cell cycle progression through inhibition of ERK1\/2 and Akt activations","volume":"75","author":"Seo","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108154_b0135","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bmc.2019.01.028","article-title":"Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives","volume":"27","author":"Yu","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108154_b0140","doi-asserted-by":"crossref","unstructured":"S. B\u00fchler, S.A. Laufer, p38 MAPK inhibitors: a patent review (2012 \u2013 2013), Expert Opin. Ther. Pat. 24 (2014) 535\u2013554.","DOI":"10.1517\/13543776.2014.894977"},{"key":"10.1016\/j.bioorg.2025.108154_b0145","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/cbdd.12581","article-title":"Synthesis and Anti-neuroinflammatory Activity of Lactone Benzoyl Hydrazine and 2-nitro-1-phenyl-1H-Indole Derivatives as p38\u03b1 MAPK Inhibitors","volume":"86","author":"Cheng","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2025.108154_b0150","doi-asserted-by":"crossref","first-page":"129302","DOI":"10.1016\/j.molstruc.2020.129302","article-title":"X-Ray structure, Hirshfeld analysis and DFT studies of two new hits of triazolyl-indole bearing alkylsulfanyl moieties","author":"Boraei","year":"2021","journal-title":"J. Mol. Struct.1225"},{"key":"10.1016\/j.bioorg.2025.108154_b0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2025.108154_b0160","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/cbdd.13997","article-title":"Quinoline\u2010based thiazolidinone derivatives as potent cytotoxic and apoptosis\u2010inducing agents through EGFR inhibition","volume":"99","author":"Nafie","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2025.108154_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105708","article-title":"Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer","volume":"122","author":"Nafie","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108154_b0170","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3390\/ph16121724","article-title":"Discovery of Potent Indolyl-Hydrazones as Kinase Inhibitors for Breast Cancer: Synthesis X-Ray Single-Crystal Analysis, and in Vitro and in Vivo Anti-Cancer Activity Evaluation","volume":"16","author":"Salama","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2025.108154_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109753","article-title":"Control of ER-positive breast cancer by ER\u03b1 expression inhibition, apoptosis induction, cell cycle arrest using semisynthetic isoeugenol derivatives","volume":"351","author":"Nafie","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2025.108154_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115828","article-title":"Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells","volume":"28","author":"Nafie","year":"2020","journal-title":"Bioorg. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825000343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825000343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T01:51:17Z","timestamp":1758851477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825000343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":36,"alternative-id":["S0045206825000343"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108154","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of new functionalized bioactive S-substituted indolyl-triazoles as cytotoxic and apoptotic agents through multi-targeted kinase inhibition","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108154"}}